This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Methods used to judge relevance and validity, and for extracting data
No systematic review appears to have been conducted. The authors stated that the REMATCH trial was the only randomised controlled trial performed to date. Bayesian prior distributions for the survival parameters were obtained from five leading experts and were adequately described in the paper.
Measure of benefits used in the economic analysis
The measure of benefits used was the quality-adjusted life-years (QALYs). The utility weights were derived from a single study (Moskowitz et al. 1997 , see 'Other Publications of Related Interest' below for bibliographic details). No additional details were provided. The QALYs were appropriately discounted.
Direct costs
The costs to the health care provider were included. These covered device cost, initial hospitalisation (including operation costs), and subsequent medical care including ambulatory and inpatient settings. Resource use and costs were derived from published studies. As the device costs had higher uncertainty, a range of costs was evaluated. Discounting of the long-term costs was adequately performed. The price year was not reported. The unit costs and the resource quantities were not reported separately.
Statistical analysis of costs
The cost data were deterministic.
Indirect Costs
Productivity costs were not included.
Currency

UK pounds sterling ().
Sensitivity analysis
The authors performed a threshold analysis of the survival parameters under which LVAD was "just" cost-effective (using QALY valuations derived from UK norms). A Bayesian partial value-of-information analysis was performed using the joint prior densities for the survival parameters, in order to arrive at a monetary valuation of the information that a future trial might uncover.
Estimated benefits used in the economic analysis
Benefits were not directly presented in this paper, but were used to calculate the expected net benefits of the intervention and expected value-of-information under different scenarios.
Cost results
Specific cost data were not directly presented in this paper, but were used to calculate the expected net benefits of the intervention and expected value-of-information under different scenarios.
